Acute myeloid leukemia
Conditions
Interventions
Experimental group:The first VA-CAG regimen treatment: oral venetoclax 100mg d1, 200mg d2, 400mg d3-14, subcutaneous injection of azacitidine 75mg·m-2·d-1, d1-7, intravenous infusion of cytarabine 10m
Sponsors
The First Affiliated Hospital of Chongqing Medical University, Department of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with a definite diagnosis of AML according to the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Non-acute Promyelocytic Leukemia) (2023 Edition); 2. The first-pass standard "3 7" scheme induces CR without reaching it; 3. ECOG score<=2; 4. Aged between 18 and 65 years old, regardless of gender; 5. No serious heart, lung, liver and kidney diseases; 6. During the study, patients can receive regular blood sampling, study-related evaluation, and appropriate clinical management at the treatment facility; 7. All subjects who have no birth plan from screening to 6 months after the end of the trial and agree to take effective non-drug contraceptive measures during the trial; 8. Mental health status, voluntary participation in clinical studies, ability to understand and willingness to sign informed consent for this trial.
Exclusion criteria
Exclusion criteria: 1. AML has the following conditions: (1) acute promyelocytic leukemia; (2) secondary AML, including AML with acute transformation of chronic myeloid leukemia, AML transformed by MDS, and treatment-related AML; (3) extramedullary infiltration of leukemia, including central infiltration; 2. Combined with other active tumors; 3. Allergy to any of the drugs involved in the project; 4. Inability to swallow tablets, malabsorption syndrome, or any condition that affects gastrointestinal absorption; 5. Participating in other clinical trials; 6. Inability to understand or cooperate with the completion of the research protocol; 7. Pregnant and lactating patients; 8. Those with active infectious diseases, autoimmune diseases, serious infections or uncontrolled mental illnesses; 9. Other conditions that are considered by the investigator to be unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease;Overall survival;Progression-free survival;Event-free survival;Incidence of grade 3 and above adverse events;Quality of life; | — |
Countries
China
Contacts
Public ContactWang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed